NASDAQ:ZBIO Zenas BioPharma Q3 2026 Earnings Date & Estimates $26.87 -1.36 (-4.82%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$26.86 -0.02 (-0.06%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Zenas BioPharma is estimated to report Q3 2026 earnings on Wednesday, November 18, 2026, before market opens. The conference call is scheduled for November 12, 2026 at 9:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 18, 2026TimeBefore Market OpensConference Call DateNovember 12, 2026Conference Call9:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Zenas BioPharma in Q3 2026Zenas BioPharma is expected to post earnings of -$1.24 per share on revenue of $1.01 million. In the same quarter a year earlier Zenas BioPharma reported -$1.22 per share. Zenas BioPharma last reported on August 13, 2026, posting -$1.77 per share and missing the -$1.12 consensus estimate. Zenas BioPharma has beaten the consensus EPS estimate in 2 of its last 6 quarters.Consensus EstimatesConsensus EPS-$1.24Expected Revenue$1.01 millionPrior-Year EPS-$1.22Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.77 (Missed by -$0.65)Last Quarter Revenue$1.00 millionEPS Beat Rate2 of last 6 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ3 2025 Earnings Report Zenas BioPharma Q3 2026 Earnings FAQ When does Zenas BioPharma report Q3 2026 earnings? Zenas BioPharma (NASDAQ:ZBIO) is estimated to report Q3 2026 earnings on Wednesday, November 18, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Zenas BioPharma's Q3 2026 earnings call? Zenas BioPharma's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Zenas BioPharma? Analysts expect Zenas BioPharma to post earnings of -$1.24 per share for Q3 2026. How much revenue is Zenas BioPharma expected to report? The consensus revenue estimate for Zenas BioPharma is $1.01 million for Q3 2026. Zenas BioPharma Earnings HeadlinesMorgan Stanley Begins Coverage on Zenas BioPharma (NASDAQ:ZBIO)October 22 at 1:42 AM | americanbankingnews.comZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 16, 2026 | globenewswire.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end. | Banyan Hill Publishing (Ad)Zenas BioPharma Highlights New Phase 3 Obexelimab DataOctober 14, 2026 | theglobeandmail.comZenas BioPharma (ZBIO) Is Down 5.1% After New Phase 3 Obexelimab IgG4-RD Data ReleaseOctober 13, 2026 | uk.finance.yahoo.comZenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related DiseaseOctober 12, 2026 | markets.businessinsider.comSee More Zenas BioPharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zenas BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zenas BioPharma and other key companies, straight to your email. Email Address About Zenas BioPharmaZenas BioPharma (NASDAQ:ZBIO) is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for autoimmune diseases and other serious immune-mediated conditions. The company’s research is centered on treatments designed to modulate B-cell activity and restore balance to the immune system. Zenas’ lead product candidate is obexelimab, an investigational bifunctional antibody designed to bind CD19 on B cells and Fc gamma receptor IIb. By engaging both targets, obexelimab is intended to inhibit pathogenic B-cell activity without broadly depleting B cells. The company is evaluating the therapy in conditions including IgG4-related disease and systemic lupus erythematosus, among other potential indications. The company was formed to advance therapies for diseases with significant unmet medical needs and conducts its clinical development activities through studies involving patients in the United States and other geographies. Zenas BioPharma became a publicly traded company on the Nasdaq under the symbol ZBIO in 2024.View Zenas BioPharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a PipelineLockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestSpotify Soars After Earnings as the Company Touts AI Benefits and Moderating CostsWhy Western Digital's AI Storage Boom Defies the Chip Sell-OffPalantir's Next Big Test Isn't a Partnership—It's the Numbers Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
